# Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

> **NCT06971211** · PHASE2 · RECRUITING · sponsor: **Jianbin Bi** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

## Key facts

- **NCT ID:** NCT06971211
- **Lead sponsor:** Jianbin Bi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971211, "Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06971211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*